How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,699 results for

Intrauterine Device

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature

Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

122. IUB? SCu300A intrauterine device for contraception

IUB? SCu300A intrauterine device for contraception IUB™ SCu300A intrauterine device for contraception IUB™ SCu300A intrauterine device for contraception NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. IUB™ SCu300A intrauterine device for contraception. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon (...) Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Contraception; Females; Intrauterine Devices Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health&Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United

2013 Health Technology Assessment (HTA) Database.

123. Lidocaine for Pain Control During Intrauterine Device Insertion

Lidocaine for Pain Control During Intrauterine Device Insertion Lidocaine for Pain Control During Intrauterine Device Insertion - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lidocaine for Pain Control (...) During Intrauterine Device Insertion The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03362905 Recruitment Status : Not yet recruiting First Posted : December 5, 2017 Last Update Posted : December 5, 2017 See Sponsor: Ain

2017 Clinical Trials

124. Vesical transmigration of an intrauterine contraceptive device: A rare case report and literature review. (PubMed)

Vesical transmigration of an intrauterine contraceptive device: A rare case report and literature review. Displacement of an intrauterine contraceptive device (IUD) is a rare and serious complication of IUD insertion. Theoretically, it can migrate to anywhere in the pelvic and abdominal cavity. However, it is not usual for an IUD to migrate to the bladder.In this case report, we reported a patient with chronic urinary symptoms caused by the migration of an IUD into the bladder. The displacement

Full Text available with Trip Pro

2017 Medicine

125. Society of Family Planning Guidelines: Postplacental insertion of intrauterine devices. (PubMed)

Society of Family Planning Guidelines: Postplacental insertion of intrauterine devices. Postplacental intrauterine device (IUD) placement, defined as IUD placement within 10 min after delivery of the placenta, is an appealing strategy for increasing access to postpartum IUDs because it does not require a separate postpartum visit. These guidelines present an evidence-based assessment of postplacental IUD placement after vaginal and cesarean delivery. Postplacental IUD insertion is safe and does

2017 Contraception

126. Frequency of 6-week follow-up appointment scheduling after intrauterine device insertion. (PubMed)

Frequency of 6-week follow-up appointment scheduling after intrauterine device insertion. Long-acting reversible contraception (LARC) is widely recommended to reduce unintended pregnancy in the USA. As intrauterine device (IUD) use increases, evaluating the role of post-insertion follow-up is important.A retrospective patient record review was conducted to assess the follow-up experience of women who had an IUD placed at the University of Kansas Medical Center from 1 January to 30 June 2015

2017 Journal of Family Planning and Reproductive Health Care

127. Six-week retention after post-placental copper intrauterine device placement. (PubMed)

Six-week retention after post-placental copper intrauterine device placement. We sought to evaluate the 6-week clinical outcomes (intrauterine device [IUD] retention, recognized expulsions, ability to visualize or palpate strings, and need for ultrasound evaluation) in women who received a TCu380A postplacental IUD (PPIUD) after vaginal (VD) or cesarean delivery (CD).We conducted a retrospective cohort study to examine the 6-week retention of TCu380A IUDs placed within 10 min of placental

2017 Contraception

128. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. (PubMed)

Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. To assess efficacy of the levonorgestrel-releasing intrauterine device (LNG-IUD) for treatment of complex atypical hyperplasia or low-grade endometrial cancer.This retrospective case series included all patients treated with the LNG-IUD for complex atypical hyperplasia or early-grade endometrial cancer from January 2003 to June 2013. Response rates were calculated

2017 Obstetrics and Gynecology

129. Social media and the intrauterine device: a YouTube content analysis. (PubMed)

Social media and the intrauterine device: a YouTube content analysis. YouTube's online archive of video testimonials related to health information are more commonly viewed than those developed by clinicians and professional groups, suggesting the importance of the patient experience to viewers. We specifically sought to examine the accuracy of information on, and projected acceptability of, the intrauterine device (IUD) from these YouTube testimonials.We searched YouTube for videos about (...) individual uploaders' IUD experiences, using the search terms 'intrauterine device', 'IUD', 'Mirena' and 'Paragard'. Given interest in user testimonials, we excluded professional and instructional videos belonging to commercial or non-profit entities. Two reviewers independently analysed the videos using a structured guide, with attention to inaccurate information.Of 86 identified videos, four videos featured clinicians and were excluded; 62 met inclusion criteria. Interrater agreement on IUD portrayal

2017 Journal of Family Planning and Reproductive Health Care

130. Anticipated Pain as a Predictor of Discomfort with Intrauterine Device Placement. (PubMed)

Anticipated Pain as a Predictor of Discomfort with Intrauterine Device Placement. Intrauterine devices have been gaining popularity for the past 2 decades. Current data report that >10% of women who use contraception are using an intrauterine device. With <1% failure rates, the intrauterine device is one of the most effective forms of long-acting reversible contraception, yet evidence shows that fear of pain during intrauterine device placement deters women from choosing an intrauterine device (...) as their contraceptive method.The objective of this analysis was to estimate the association between anticipated pain with intrauterine device placement and experienced pain. We also assessed other factors associated with increased discomfort during intrauterine device placement. We hypothesized that patients with higher levels of anticipated pain would report a higher level of discomfort during placement.We performed a secondary analysis of the Contraceptive CHOICE Project. There were 9256 patients enrolled

Full Text available with Trip Pro

2017 American Journal of Obstetrics and Gynecology

131. Intrauterine Device Use and Cervical Cancer Risk: A Systematic Review and Meta-analysis. (PubMed)

Intrauterine Device Use and Cervical Cancer Risk: A Systematic Review and Meta-analysis. To estimate the association between use of an intrauterine device (IUD) and risk of cervical cancer by subjecting existing data to critical review, quantitative synthesis, and interpretation.We searched PubMed, Web of Science, ClinicalTrials.gov, and catalogs of scientific meetings and abstracts, theses, and dissertations queried from inception through July 2016.Examination of abstracts from 225 reports

2017 Obstetrics and Gynecology

132. Women's experiences with immediate postpartum intrauterine device insertion: A mixed methods study. (PubMed)

Women's experiences with immediate postpartum intrauterine device insertion: A mixed methods study. To describe women's pain and experiences with immediate postpartum intrauterine device (IUD) insertion (IPPI) following vaginal delivery using a ring forceps insertion technique.This observational mixed-methods study included women who underwent successful IPPI using ring forceps, with and without epidural analgesia. To describe women's pain during the procedure, we recruited women during

2017 Contraception

133. Practice Bulletin No. 186 Summary: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. (PubMed)

Practice Bulletin No. 186 Summary: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Intrauterine devices and contraceptive implants, also called long-acting reversible contraceptives (LARC), are the most effective reversible contraceptive methods. The major advantage of LARC compared with other reversible contraceptive methods is that they do not require ongoing effort on the part of the patient for long-term and effective use. In addition, after the device is removed

2017 Obstetrics and Gynecology

134. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. (PubMed)

Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Intrauterine devices and contraceptive implants, also called long-acting reversible contraceptives (LARC), are the most effective reversible contraceptive methods. The major advantage of LARC compared with other reversible contraceptive methods is that they do not require ongoing effort on the part of the patient for long-term and effective use. In addition, after the device is removed

2017 Obstetrics and Gynecology

135. Postplacental intrauterine device expulsion by 12 weeks: A prospective cohort study. (PubMed)

Postplacental intrauterine device expulsion by 12 weeks: A prospective cohort study. An intrauterine device placed immediately following a delivery can serve as an effective and safe contraceptive strategy in the postpartum period. There is limited evidence that the levonorgestrel intrauterine system may have a higher rate of expulsion compared to the copper intrauterine device; however, rates of expulsion for these 2 intrauterine device types have not been compared directly.We sought (...) to compare expulsion rates by 12 weeks' postpartum for the levonorgestrel intrauterine system and copper intrauterine device.We enrolled women who received postplacental intrauterine devices at 2 urban hospitals. Eligible women were ≥18 years old, English- or Spanish-speaking, with singleton vaginal delivery at ≥35 weeks' gestation. Intrauterine devices were inserted within 10 minutes of placental delivery by trained providers using ring forceps or the operator's hand. Intrauterine device location

2017 American Journal of Obstetrics and Gynecology

136. One-year continuation of copper or levonorgestrel intrauterine devices initiated at the time of emergency contraception. (PubMed)

One-year continuation of copper or levonorgestrel intrauterine devices initiated at the time of emergency contraception. This study compares 1-year intrauterine device (IUD) continuation among women presenting for emergency contraception (EC) and initiating the copper (Cu T380A) IUD or the levonorgestrel (LNG) 52 mg IUD plus 1.5 mg oral LNG.This cohort study enrolled 188 women who presented at a single family planning clinic in Utah between June 2013 and September 2014 and selected either (...) for 147 (84%) participants, 33 (22%) had requested removals, 13 (9%) had an expulsion and declined reinsertion, 3 (2%) had a pregnancy with their IUD in place and 98 (67%) were still using their device. Continuation rates did not differ by IUD type; 60% of Cu T380A IUD users and 70% of LNG 52 mg IUD plus oral LNG users were still using their device at 12 months (adjusted hazard ratio 0.72, 95% confidence interval 0.40-1.3).Two-thirds of women who chose IUD placement at the EC clinical encounter

Full Text available with Trip Pro

2017 Contraception

137. Short-term copper intrauterine device placement improves the implantation and pregnancy rates in women with repeated implantation failure. (PubMed)

Short-term copper intrauterine device placement improves the implantation and pregnancy rates in women with repeated implantation failure. To study if hysteroscopy and short-term copper intrauterine device placement (Cu-IUD) improves the pregnancy rates of women with repeated implantation failure (RIF) undergoing frozen-thawed embryo transfer (FET).Retrospective study.Medical university hospital.Infertile women with at least two implantation failures with the use of at least one good-quality (...) embryo.All patients received operative hysteroscopy in the follicular cycle, and if endometrial polyps, polypoid endometrium, or intrauterine adhesions were found they were removed. In some patients, a Cu-IUD was inserted immediately after hysteroscopy and removed after two menstrual periods before embryo implantation. All patients underwent in vitro fertilization or intracytoplasmic sperm injection and FET.Clinical pregnancy and implantation rates.A total of 440 women with a mean age of 33.42 ± 4.45

2017 Fertility and Sterility

138. Uterine perforation by intrauterine devices: a 16-year review. (PubMed)

Uterine perforation by intrauterine devices: a 16-year review. One of the major concerns with the insertion of intrauterine devices is uterine perforation. Though uncommon, it can be debilitating and result in failure of the device. In this article we review uterine perforation with intrauterine contraception (IUC) in a community clinic in the UK over a 16-year period.We prospectively collected data on uterine perforations for the years 2000-2015, reviewed associated factors and calculated (...) limits. Twenty-eight of the perforations were in parous women, 87% of whom were within 18 weeks of delivery, peaking at 13 weeks postpartum. Twenty of these were in breastfeeding women. In 3/28 cases for which we have outcome data the device was adherent to or had perforated either the bladder or bowel.Our perforation rate is consistent with other studies. Most of our perforations were within 18 weeks of childbirth, earlier than in a recent major study. We cannot tell from our data if there is a true

2017 Journal of Family Planning and Reproductive Health Care

139. Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. (PubMed)

Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. To assess the endometrial response rates to treatment with the levonorgestrel intrauterine device in post-menopausal women with atypical hyperplasia/endometrial intraepithelial neoplasia and grade 1 endometrioid (AH/EC) endometrial carcinoma who are not surgical candidates.Chart review was undertaken of patients with AH/EC (...) who underwent levonorgestrel intrauterine device insertion by a gynecologic oncologist within two academic health systems between 2002 and 2013. When available, tissue blocks were evaluated with immunohistochemical staining for progesterone receptor expression.A total of 41 patients received treatment for AH/EC with the levonorgestrel intrauterine device. Follow up sufficient to assess response occurred in 36 women (88%). Complete response was documented in 18 of 36 women (50%), no response in 8

2017 Gynecologic Oncology

140. Insertion of intrauterine devices after cesarean section: a systematic review update. (PubMed)

Insertion of intrauterine devices after cesarean section: a systematic review update. Women who undergo a cesarean section (CS) are in a unique position to receive the intrauterine contraceptive device (IUD). They may also want to use the IUD as a long-acting reversible contraceptive method provided the IUD is safe and effective in the presence of a CS scar.We researched and reviewed the MEDLINE, POPLINE, Google Scholar, and ClinicalTrials.gov databases from January 1968 to June 2015.Eligible (...) studies reported event rates or practical problems relating to IUD usage in post-placental or interval insertion (>90 days) after CS. Studies with ≥20 subjects were included.Analysis of eligible data collected from the search followed the PRISMA guidelines.Twelve eligible studies of post-placental IUD insertion after CS included four randomized controlled trials of post-placental versus delayed insertion. Women randomized to delayed insertion were less likely to receive a device. Six studies examined

Full Text available with Trip Pro

2017 International journal of women's health

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>